Clinical and treatment-related determinants of advanced-stage femoral head osteonecrosis following COVID-19: a five-year retrospective cohort study Authors: Volkan Kizilkaya, Sefa Erdem Karapinar Published: 2026 ABSTRACT AbstractBackgroundThe aim of this study was to evaluate clinical and treatment-related factors associated with advanced-stage femoral head avascular necrosis (AVN) (Ficat stage III–IV) in patients who developed osteonecrosis following COVID-19 infection, based on long-term follow-up data.MethodsThis single-center retrospective cohort study included patients diagnosed with femoral head AVN after confirmed COVID-19 infection who had at least five years of clinical and radiological follow-up. Demographic characteristics, comorbidities, clinical severity of COVID-19, duration of hospitalization, intensive care unit (ICU) requirement, type and duration of systemic corticosteroid therapy, and duration of antiviral treatment were recorded. AVN was staged according to the Ficat and Arlet classification. Patients were divided into early-stage (stage I–II) and advanced-stage (stage III–IV) groups. Independent predictors of advanced-stage AVN were evaluated using logistic regression analysis. Receiver operating characteristic (ROC) analysis was performed to determine the discriminatory ability of antiviral treatment duration for advanced-stage disease. Time to osteonecrosis was defined as the interval between confirmed RT-PCR diagnosis of COVID-19 and first MRI confirmation of femoral head AVN.ResultsA total of 40 patients were included. Advanced-stage AVN was significantly associated with longer hospitalization duration, prolonged corticosteroid use, extended antiviral treatment, and the presence of hypertension. Multivariable logistic regression analysis identified hypertension, hospitalization duration, steroid treatment duration, and antiviral treatment duration as independent risk factors for advanced-stage AVN. ROC analysis demonstrated that an antiviral treatment duration ≥ 9.5 days showed excellent discriminatory performance for advanced-stage AVN (AUC = 0.950). These results reflect associations within a selected cohort of patients with post-COVID AVN and do not imply a direct causal relationship. However, this finding should be interpreted with caution due to the limited sample size and should be considered exploratory rather than definitive.ConclusionsIn patients who develop femoral head AVN following COVID-19 infection, disease progression appears closely related to the clinical severity of COVID-19 and overall treatment burden. Patients with severe COVID-19 requiring prolonged hospitalization and extended treatment exposure should be carefully monitored for progression to advanced-stage AVN. The identified cut-off value should be considered hypothesis-generating rather than definitive.Keywords: COVID-19, Femoral head, Avascular necrosis, Corticosteroids Introduction Avascular necrosis (AVN) of the femoral head is a progressive and irreversible ischemic bone disorder resulting from compromised blood supply to the subchondral region of the femoral head. The pathological process involves osteocyte death, bone marrow necrosis, and subsequent subchondral fracture, ultimately leading to femoral head collapse and secondary hip osteoarthritis. Clinically, AVN represents one of the major causes of total hip arthroplasty, particularly in young and active individuals [1, 2]. Systemic corticosteroid use, excessive alcohol consumption, hematologic disorders, and trauma-related vascular injury are among the most commonly reported risk factors for AVN [3, 4]. These factors share a common pathophysiological pathway characterized by microvascular compromise, increased intraosseous pressure, and progressive ischemic damage within the bone. Corticosteroids, in particular, have been shown to induce hypertrophy of bone marrow adipocytes, leading to sinusoidal compression and impaired femoral head perfusion [5]. Following the Coronavirus Disease 2019 (COVID-19) pandemic, an increasing number of femoral head AVN cases have been reported across different centers. The occurrence of AVN within months after COVID-19 infection has raised concerns regarding a potential association between SARS-CoV-2 infection and osteonecrosis. However, it remains unclear whether this association is attributable to the direct effects of the virus, the systemic inflammatory response, or treatment-related factors [3, 6–8]. Systemic corticosteroids have been widely used in moderate-to-severe COVID-19 to reduce mortality. The relationship between corticosteroid exposure and AVN has long been established, with risk increasing proportionally to cumulative dose and duration of therapy. During the previous SARS outbreak, the incidence of femoral head AVN reached up to 20–30% among patients treated with high-dose and prolonged steroid regimens. This historical experience underscores the importance of evaluating the long-term musculoskeletal consequences of similar therapeutic strategies applied during the COVID-19 pandemic [9–11]. Beyond steroid exposure, COVID-19 itself possesses pathophysiological characteristics that may predispose patients to AVN development and progression. The disease is characterized by endothelial dysfunction, diffuse microthrombosis, and a hypercoagulable state. Microvascular perfusion impairment secondary to endothelial injury may increase ischemic risk in anatomically vulnerable regions such as the femoral head, which relies on terminal blood supply. Therefore, post-COVID AVN should be evaluated not only in the context of steroid exposure but also in relation to disease severity and systemic vascular effects. Most currently available studies on post-COVID femoral head AVN consist primarily of case reports or small series with short-term follow-up [12–14]. These reports mainly describe the occurrence of osteonecrosis, while data regarding stage distribution, progression to advanced disease, and long-term clinical outcomes remain limited. In particular, factors associated with progression to advanced-stage AVN (Ficat stage III–IV) have not been adequately clarified. Unlike previous reports focusing primarily on the occurrence of osteonecrosis after COVID-19 infection, the present study specifically aims to identify determinants of progression to advanced-stage disease during long-term follow-up. Understanding factors associated with femoral head collapse (Ficat stage III–IV), rather than mere incidence, may provide clinically actionable insights for risk stratification and follow-up strategies. Materials and methods Study design and patient selection This study was designed as a single-center, retrospective observational cohort study evaluating patients diagnosed with femoral head avascular necrosis (AVN) following confirmed COVID-19 infection. A total of 54 patients diagnosed with femoral head AVN after confirmed COVID-19 infection were initially assessed for eligibility. 8 patients were excluded due to a prior history of osteonecrosis before COVID-19 infection, and 6 patients were excluded due to follow-up duration shorter than five years. Finally, 40 patients met the inclusion criteria and were included in the final analysis. The patient selection process is summarized in Fig. 1. The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the local institutional ethics committee (HRU/25.20.74). Due to the retrospective design of the study, the requirement for informed consent was waived by the ethics committee. Flow diagram of patient selection and group allocation COVID-19 infection was confirmed by a positive reverse transcription polymerase chain reaction (RT-PCR) test. Patients who were diagnosed with femoral head AVN after COVID-19 infection and had at least five years of clinical and radiological follow-up were included in the study. Patients with trauma-related AVN, a prior history of osteonecrosis, or insufficient follow-up duration were excluded. Data collection Demographic data including age, sex, and body mass index (BMI) were recorded. Comorbidities such as diabetes mellitus (DM), hypertension (HT), coronary artery disease (CAD), hyperlipidemia, chronic obstructive pulmonary disease (COPD), and asthma were obtained from medical records. Smoking and alcohol consumption status were also documented. Clinical severity of COVID-19 was assessed based on hospitalization status, duration of hospitalization (days), requirement for intensive care unit (ICU) admission, need for supplemental oxygen therapy, and requirement for mechanical ventilation. Within the scope of COVID-19 treatment, the type, cumulative dose, and duration of systemic corticosteroid therapy (dexamethasone and/or methylprednisolone) were recorded. Antiviral treatment duration (favipiravir and/or remdesivir) was calculated in days. Radiological assessment The diagnosis of femoral head AVN was established based on magnetic resonance imaging (MRI) findings. Time to AVN diagnosis was defined as the interval (in months) between confirmed COVID-19 diagnosis and first MRI-based confirmation of femoral head osteonecrosis. Disease staging was performed according to the Ficat and Arlet classification system [15]. For statistical analyses, patients were categorized into: Early-stage AVN (Ficat stage I–II). Early-stage AVN (Ficat stage I–II). Advanced-stage AVN (Ficat stage III–IV). Advanced-stage AVN (Ficat stage III–IV). Ficat stages III and IV were analyzed together due to similar clinical implications related to femoral head collapse and the limited number of patients in each individual stage. Bilateral involvement and the presence of concomitant knee osteochondral pathology were additionally recorded. The mean duration of follow-up after COVID-19 infection was approximately five years, allowing long-term assessment of disease progression. Statistical analysis Statistical analyses were performed using IBM SPSS Statistics (version 27.0; IBM Corp., Armonk, NY, USA). The normality of continuous variables was assessed using the Shapiro–Wilk test. Normally distributed continuous variables were expressed as mean ± standard deviation (SD), whereas non-normally distributed variables were presented as median with interquartile range (IQR). For comparisons between two independent groups: Independent samples t-test was used for normally distributed continuous variables. Independent samples t-test was used for normally distributed continuous variables. Mann–Whitney U test was used for non-normally distributed continuous variables. Mann–Whitney U test was used for non-normally distributed continuous variables. Pearson’s chi-square test was applied for categorical variables. Pearson’s chi-square test was applied for categorical variables. Fisher’s exact test was used when expected cell counts were low. Fisher’s exact test was used when expected cell counts were low. To identify independent predictors of advanced-stage AVN (stage III–IV), binary logistic regression analysis was performed using the backward likelihood ratio (Backward: LR) method. Given the limited number of advanced-stage cases and the potential collinearity among severity-related variables, only clinically meaningful parameters were included in the multivariable model. The regression analysis was therefore considered exploratory and hypothesis-generating in nature. ICU admission and mechanical ventilation were not included in the multivariable model due to complete or near-complete separation between groups. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the discriminatory ability of antiviral treatment duration (days) for identifying advanced-stage AVN. The area under the curve (AUC) with 95% confidence intervals was calculated. A p-value < 0.05 was considered statistically significant. Results A total of 40 patients who developed femoral head avascular necrosis (AVN) following confirmed COVID-19 infection were included in the final analysis. Patients were categorized into early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) groups to evaluate factors associated with disease progression. Baseline demographic characteristics, COVID-19–related clinical severity indicators, treatment parameters, and AVN-related radiological findings were analyzed and compared between groups. The baseline demographic and COVID-19–related clinical characteristics of the study population are summarized in Table 1. The cohort consisted of an equal distribution of males and females, with a high proportion of hospitalized patients reflecting predominantly moderate-to-severe COVID-19 cases. Most patients required oxygen therapy, and nearly all received systemic corticosteroids and antiviral treatment. Table 1Baseline demographic and COVID-19–related clinical characteristics of the study populationVariable n %Sex Male2050.0 Female2050.0Smoking status No2050.0 Yes2050.0Alcohol consumption No2152.5 Yes1947.5Hospitalization No820.0 Yes3280.0ICU admission No2562.5 Yes1537.5Oxygen therapy No615.0 Yes3485.0Mechanical ventilation No3690.0 Yes410.0Dexamethasone use No12.5 Yes3997.5Methylprednisolone use No2972.5 Yes1127.5Favipiravir use Yes40100.0Remdesivir use No2972.5 Yes1127.5 Baseline demographic and COVID-19–related clinical characteristics of the study population Comorbidities and AVN-related clinical characteristics are presented in Table 2. None of the patients received molnupiravir therapy. The majority of patients had no history of diabetes mellitus, hypertension, hyperlipidemia, COPD/asthma, or coronary artery disease. Right-sided AVN was the most common presentation, while bilateral involvement was observed in 27.5% of cases. According to the Ficat classification, stage I disease was the most frequent stage at diagnosis, and advanced-stage AVN (stage III–IV) accounted for one-quarter of the cohort. Knee osteochondral pathology was identified in a minority of patients, and all affected cases demonstrated bilateral involvement. Table 2Comorbidities and AVN-related clinical characteristicsVariable n %Molnupiravir use No40100.0Diabetes mellitus No3690.0 Yes410.0Hypertension No3382.5 Yes717.5Hyperlipidemia No3792.5 Yes37.5COPD / Asthma No40100.0Coronary artery disease No3792.5 Yes37.5AVN laterality Right2152.5 Left820.0 Bilateral1127.5AVN stage (Ficat classification) Stage I1742.5 Stage II1332.5 Stage III512.5 Stage IV512.5Knee osteochondral pathology No3587.5 Yes512.5Knee involvement (in affected cases) Bilateral5100.0 Comorbidities and AVN-related clinical characteristics Descriptive statistics of continuous variables are presented in Table 3. The mean age of the cohort was 50.9 years and the duration of follow-up after COVID-19 infection exceeded five years in all patients. Table 3Descriptive statistics of continuous variables in the study populationVariableMeanSDMedianMinMaxAge (years)50.9211.3450.531.070.0Body mass index (kg/m²)32.906.0033.022.048.0Hospitalization duration (days)7.426.685.00.021.0Total dexamethasone dose (mg)16.0520.750.00.060.0Total methylprednisolone dose (mg)925.001607.470.00.05000.0Steroid treatment duration (days)3.604.920.00.015.0Antiviral treatment duration (days)8.703.117.05.014.0Duration of follow-up after COVID-19 (months)56.903.5257.549.063.0 Descriptive statistics of continuous variables in the study population There was no statistically significant association between AVN stage and sex, smoking status, hospitalization status, oxygen therapy, or dexamethasone use (p > 0.05). Alcohol consumption was significantly associated with AVN stage (p = 0.044). Alcohol use was more frequent in the early-stage group, whereas alcohol non-use predominated in the advanced-stage group. A strong association was observed between AVN stage and intensive care unit (ICU) admission (p < 0.001). All patients in the advanced-stage group required ICU admission, while the majority of early-stage patients did not. Mechanical ventilation requirement was also significantly associated with advanced-stage disease (p < 0.001). None of the early-stage patients required mechanical ventilation, whereas 40% of advanced-stage patients did (Table 4). Table 4Comparison of categorical variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVNVariableStage I–II (n = 30) n (%)Stage III–IV (n = 10) n (%)p-valueSex0.144 Male17 (56.7)3 (30.0) Female13 (43.3)7 (70.0)Smoking status0.465 No16 (53.3)4 (40.0) Yes14 (46.7)6 (60.0)Alcohol consumption0.044 No13 (43.3)8 (80.0) Yes17 (56.7)2 (20.0)Hospitalization0.068 No8 (26.7)0 (0.0) Yes22 (73.3)10 (100.0)ICU admission< 0.001 No25 (83.3)0 (0.0) Yes5 (16.7)10 (100.0)Oxygen therapy0.125 No6 (20.0)0 (0.0) Yes24 (80.0)10 (100.0)Mechanical ventilation< 0.001 No30 (100.0)6 (60.0) Yes0 (0.0)4 (40.0)Dexamethasone use0.559 No1 (3.3)0 (0.0) Yes29 (96.7)10 (100.0) Comparison of categorical variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVN No significant association was observed between AVN stage and hyperlipidemia (p > 0.05). Advanced-stage AVN was significantly associated with methylprednisolone use and remdesivir treatment (p < 0.001 for both). In addition, diabetes mellitus, hypertension, and coronary artery disease were significantly more frequent in the advanced-stage group. A strong association was also observed between AVN stage and bilateral involvement (p < 0.001). All patients in the advanced-stage group demonstrated bilateral disease. Furthermore, the presence of knee osteochondral pathology was significantly associated with advanced-stage AVN (p < 0.001) (Table 5). Table 5Comparison of additional categorical variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVNVariableStage I–II (n = 30) n (%)Stage III–IV (n = 10) n (%)p-valueMethylprednisolone use< 0.001 No29 (96.7)0 (0.0) Yes1 (3.3)10 (100.0)Remdesivir use< 0.001 No29 (96.7)0 (0.0) Yes1 (3.3)10 (100.0)Diabetes mellitus< 0.001 No30 (100.0)6 (60.0) Yes0 (0.0)4 (40.0)Hypertension< 0.001 No29 (96.7)4 (40.0) Yes1 (3.3)6 (60.0)Hyperlipidemia0.083 No29 (96.7)8 (80.0) Yes1 (3.3)2 (20.0)Coronary artery disease0.002 No30 (100.0)7 (70.0) Yes0 (0.0)3 (30.0)AVN laterality< 0.001 Right21 (70.0)0 (0.0) Left8 (26.7)0 (0.0) Bilateral1 (3.3)10 (100.0)Knee osteochondral pathology< 0.001 No30 (100.0)5 (50.0) Yes0 (0.0)5 (50.0) Comparison of additional categorical variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVN There were no statistically significant differences between early-stage and advanced-stage AVN groups in terms of age, body mass index, or time to AVN diagnosis (p > 0.05). The interval between confirmed COVID-19 diagnosis and MRI-based AVN detection was comparable between groups and did not show a statistically significant difference. However, hospitalization duration, total dexamethasone dose, steroid treatment duration, and antiviral treatment duration were significantly higher in the advanced-stage group compared with the early-stage group (p < 0.05 for all comparisons) (Table 6). Table 6Comparison of continuous variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVNVariableStage I–II (n = 30) Mean ± SDMedian [IQR]Stage III–IV (n = 10) Mean ± SDMedian [IQR]p-valueAge (years)51.00 ± 11.7750.5 [20.8]50.70 ± 10.5651.5 [15.5]0.943Body mass index (kg/m²)32.02 ± 5.4832.5 [9.0]35.50 ± 7.0237.5 [10.0]0.115Hospitalization duration (days)4.50 ± 4.683.5 [5.3]16.20 ± 2.9316.5 [5.3]< 0.001Total dexamethasone dose (mg)23.25 ± 7.4724.0 [12.0]45.60 ± 13.3242.0 [30.0]0.002Steroid treatment duration (days)4.25 ± 1.904.0 [2.0]11.00 ± 3.0510.5 [6.3]< 0.001Antiviral treatment duration (days)7.23 ± 1.947.0 [0.0]13.10 ± 0.9913.5 [2.0]< 0.001Time to AVN diagnosis (months)56.86 ± 3.8058.0 [7.0]57.00 ± 2.6757.0 [4.3]0.919 Comparison of continuous variables between early-stage (Ficat I–II) and advanced-stage (Ficat III–IV) AVN Independent samples t-test was used for normally distributed variables; Mann–Whitney U test was used for non-normally distributed variables. Multivariable logistic regression analysis using the backward likelihood ratio method identified hypertension, hospitalization duration, antiviral treatment duration, and steroid treatment duration as independent predictors of advanced-stage AVN. Hypertension was associated with a significantly increased risk of advanced-stage disease (OR = 13.50). Each additional day of hospitalization increased the risk by approximately 63%. Similarly, each additional day of antiviral therapy was associated with a more than two-fold increase in risk, while prolonged steroid treatment was also significantly associated with disease progression (Table 7). Table 7Multivariable logistic regression analysis for predictors of advanced-stage AVN (Ficat III–IV)VariableOdds Ratio (OR)95% CIp-valueHypertension13.504.10–28.850.002Hospitalization duration (days)1.631.15–2.310.006Antiviral treatment duration (days)2.411.43–4.05< 0.001Steroid treatment duration (days)1.841.04–3.280.037Backward likelihood ratio method was used for model construction Multivariable logistic regression analysis for predictors of advanced-stage AVN (Ficat III–IV) Backward likelihood ratio method was used for model construction An optimal antiviral treatment duration cut-off value of ≥ 9.5 days was identified for discriminating advanced-stage AVN, demonstrating excellent discriminatory performance (AUC = 0.950; 95% CI 0.879–0.999; p < 0.001). These findings reflect the characteristics of a selected cohort of patients with severe COVID-19 and should therefore be interpreted within this specific clinical context rather than generalized to all post-COVID osteonecrosis cases (Table 8). Table 8Receiver operating characteristic (ROC) analysis of antiviral treatment duration for predicting advanced-stage AVNAUCStandard Error95% CIp-valueOptimalCut-offAntiviral treatment duration (days)0.9500.0360.879–0.999< 0.001≥ 9.5 days Receiver operating characteristic (ROC) analysis of antiviral treatment duration for predicting advanced-stage AVN Discussion Unlike previous studies that primarily focused on the occurrence of osteonecrosis following COVID-19 infection, the present study specifically evaluates long-term progression to advanced-stage disease over an extended follow-up period. The principal finding of this study is that progression to advanced-stage femoral head avascular necrosis (Ficat stage III–IV) following COVID-19 infection is significantly associated with the clinical severity of COVID-19 and overall treatment burden. Specifically, longer hospitalization duration, prolonged corticosteroid exposure, extended antiviral treatment, and the presence of hypertension were independently associated with advanced-stage disease. Due to the retrospective design of this study, these findings should be interpreted as associations rather than causal relationships. Given that these variables largely reflect COVID-19 severity and are closely interrelated, the results suggest that severe systemic disease burden may play a central role in the progression of osteonecrosis. The observed association between ICU admission and advanced-stage AVN further supports the hypothesis that systemic disease severity plays a critical role in disease progression. Although an increasing number of studies have reported cases of femoral head AVN after COVID-19 infection, most of these publications have primarily focused on the occurrence of osteonecrosis rather than its progression [6]. In contrast, the present study evaluated long-term follow-up data and specifically examined factors associated with advanced-stage disease. This distinction is clinically relevant, as femoral head collapse (Ficat stage III–IV) is strongly associated with worse functional outcomes and a higher likelihood of surgical intervention. The role of corticosteroids in AVN pathogenesis has been well established [9]. During the SARS outbreak, high-dose and prolonged steroid regimens were associated with markedly increased AVN incidence [16]. In the present study, steroid treatment duration was identified as an independent predictor of advanced-stage AVN, supporting the concept that cumulative exposure contributes not only to disease development but also to its progression. However, steroid exposure in COVID-19 patients is closely linked to disease severity, and therefore its contribution should be interpreted within the broader context of systemic illness burden. One of the most notable findings of this study was the association between antiviral treatment duration and advanced-stage AVN. Although antiviral treatment duration emerged as an independent variable in regression analysis, this finding should not be interpreted as evidence of a direct causal relationship. Currently, there is no strong evidence suggesting a direct osteonecrotic effect of antiviral agents. Therefore, prolonged antiviral therapy is more likely to represent a surrogate marker of severe COVID-19 rather than a direct etiological factor. Given the close interrelationship between hospitalization duration, intensive care requirement, steroid exposure, and antiviral treatment, these variables should be interpreted as surrogate markers of disease severity rather than independent causal predictors. The observed associations likely reflect the overall systemic burden of severe COVID-19 rather than direct mechanistic effects of individual treatments. Patients with more severe disease courses tend to receive extended antiviral treatment, reflecting sustained systemic inflammation and physiological stress. Consequently, antiviral treatment duration should be interpreted as an indirect indicator of disease severity rather than a causal determinant of osteonecrosis progression. COVID-19 is characterized by endothelial dysfunction, microvascular thrombosis, and a hypercoagulable state. These vascular abnormalities may compromise microcirculation in terminally supplied regions such as the femoral head. Notably, all advanced-stage cases in this cohort demonstrated bilateral involvement, suggesting a systemic rather than purely local mechanism. The combination of endothelial injury, microthrombotic events, and inflammatory-mediated vascular compromise may accelerate ischemic damage and structural collapse in susceptible individuals. Hypertension emerged as a strong independent predictor of advanced-stage AVN. Chronic hypertension is known to impair microvascular function and contribute to endothelial dysfunction. When superimposed on COVID-19–related vascular injury, hypertension may further exacerbate perfusion deficits in the femoral head, thereby accelerating disease progression. The higher prevalence of alcohol non-use in the advanced-stage group should not be interpreted as protective; rather, it likely reflects confounding effects related to disease severity and hospitalization patterns [17]. The ROC analysis demonstrated a high discriminatory performance of antiviral treatment duration (AUC = 0.950) for identifying advanced-stage disease, with a cut-off value of ≥ 9.5 days. While this finding is clinically intriguing, the limited number of advanced-stage cases necessitates cautious interpretation. The identified threshold should be considered hypothesis-generating and requires validation in larger, multicenter cohorts before any clinical application. The major strength of this study lies in its long-term follow-up period, allowing evaluation of disease progression rather than mere occurrence of osteonecrosis, which has been a key limitation of previous reports. Nevertheless, several limitations should be acknowledged. First, the retrospective and single-center design may introduce selection bias and limit generalizability. In addition, potential confounding related to disease severity and treatment allocation cannot be fully excluded. Second, the relatively small sample size, particularly in the advanced-stage group, may increase the risk of model instability and overestimation of effect sizes. Third, the absence of a non-COVID control group prevents direct comparison with conventional steroid-related AVN. Finally, variations in COVID-19 treatment protocols throughout the pandemic may have influenced treatment duration and cumulative exposure. Despite these limitations, the findings suggest that post-COVID femoral head AVN should be considered within the broader framework of systemic disease severity and vascular dysfunction. Clinically, patients requiring prolonged hospitalization and extended systemic therapy should be considered for structured long-term musculoskeletal surveillance, even in the absence of early radiographic collapse. Monitoring strategies in patients with severe COVID-19, particularly those requiring prolonged hospitalization and extended treatment exposure, may facilitate earlier detection of progressive osteonecrosis and potentially mitigate the risk of femoral head collapse. Therefore, the regression and ROC findings should be interpreted as exploratory and hypothesis-generating rather than definitive. In addition, the absence of external validation limits the generalizability of these findings, and further prospective multicenter studies are required to confirm these results. Conclusion This study demonstrates that femoral head avascular necrosis developing after COVID-19 infection may follow a progressive course closely associated with the clinical severity of the initial illness and overall treatment burden. Prolonged hospitalization, extended corticosteroid exposure, longer antiviral treatment duration, and the presence of hypertension were identified as independent factors associated with progression to advanced-stage disease. These associations should not be interpreted as direct causal relationships but rather as reflections of systemic disease severity and treatment intensity in patients with moderate-to-severe COVID-19. These findings emphasize the importance of long-term clinical and radiological monitoring in patients who experienced severe COVID-19, particularly those requiring intensive care and prolonged therapeutic interventions. Early recognition of osteonecrosis in high-risk individuals may help guide timely management strategies and potentially reduce the risk of femoral head collapse and subsequent surgical intervention. Given the exploratory nature of the regression and ROC analyses and the limited sample size, the identified associations should be validated in larger, prospective multicenter studies before being incorporated into risk stratification models. Acknowledgements Not applicable. Abbreviations Coronavirus disease Severe Acute Respiratory Syndrome Coronavirus Avascular necrosis Body mass index Intensive care unit Receiver operating characteristic Authors’ contributions Study conception and design: S.E.K., V.K.Clinical data collection and patient evaluation: S.E.K.Statistical analysis: V.K.Interpretation of data: S.E.K.Manuscript drafting: S.E.K.Critical revision of the manuscript: V.K.Final approval of the manuscript: S.E.K. Funding The authors declare that no funding was received for this study. Data availability Data supporting the findings are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Harran University Ethics Committee (HRU/25.20.74). Due to the retrospective design of the study, the requirement for informed consent was waived by the ethics committee. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data supporting the findings are available from the corresponding author upon reasonable request.